3 results
Approved WMOCompleted
To assess the efficacy of secukinumab 300 mg s .c. vs. placebo in patients with overuse rotator cuff tendinopathy in relieving clinical symptoms at week 14
Approved WMOCompleted
Primary Objective:The primary objective of the study is to compare overall survival between the ASA404 plus docetaxel group and the placebo plus docetaxel group Key Secondary Objectives:To compare Progression-Free Survival (PFS) and the Overall…
Approved WMORecruiting
The primary objective is reducing treatment-related morbidity and mortality without adversely impacting DFS in Ph+ ALL patients, classified as Standard Risk (SR) based on low minimal residual disease (MRD) at week 10-12 of therapy.Because there is…